1. Argentina Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Instituto Rosenbusch SA Class B

Instituto Rosenbusch SA Class B

149.00
ARS
-3.00
(-1.97%)
-8.33EPS
6.73BMarket Cap
Instituto Rosenbusch SA Class B
BYMA:ROSE.CI
(Buenos Aires Stock Exchange)

Recent

price

149.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ARS
1.93
1.7
1.96
2.01
2.53
3.18
3.93
6.43
10.8
13.16
19.8
35.75
100.4
231.52
255.59
150.36
179.86
Revenue per Share
0.1
0.16
0.22
-0.22
0.23
- -
0.24
-1.17
0.03
-2.85
-0.6
-0.9
-0.59
28.78
-43.78
-107.95
-10.22
Basic EPS, GAAP
0.04
-0.21
-0.31
-0.27
0.12
-0.26
- -
-0.15
-0.85
0.39
1.47
1.27
1.66
5.07
16.59
9.34
20.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.65
1.38
1.51
1.29
1.5
1.52
4.72
5.55
6.28
5.06
8.98
8.1
26.53
97.89
87.8
-18.79
180.08
Book Value per Share
1.65
1.38
1.5
1.29
1.5
1.52
4.72
5.55
6.28
5.06
8.98
8.09
26.29
97.2
87.8
-18.79
180.08
Tangible Book Value per Share
30
42
42
42
43
43
43
43
43
43
43
43
43
43
43
43
43
Basic Weighted Avg Shares
57
72
83
85
108
135
167
274
460
561
843
1,523
4,276
9,860
10,886
6,404
7,660
Sales/Revenue/Turnover
6.38
14.75
6.5
4.86
2.79
-2.01
8.43
-18.82
0.34
-5.94
9.07
1.06
20.47
1.48
23.54
-49.08
-44.25
Operating Margin (%)
1
2
4
2
4
1
3
13
8
19
24
63
175
-58
-82
163
78
Depreciation Expense
3
7
9
-9
10
- -
10
-50
1
-121
-26
-38
-25
1,226
-1,864
-4,598
-435
Net Income, GAAP
27.73
27.95
13.4
- -
4.5
35.71
11.97
- -
53.84
- -
378.98
- -
229.42
9.83
- -
- -
- -
Effective Tax Rate (%)
5.19
9.67
11.2
-10.71
9.04
-0.11
6.07
-18.17
0.27
-21.66
-3.04
-2.5
-0.59
12.43
-17.13
-71.8
-5.68
Profit Margin (%)
38
44
64
49
58
63
158
177
194
51
57
541
1,418
4,509
3,429
-872
3,538
Working Capital
- -
- -
17
13
11
12
7
15
8
26
7
335
922
1,302
1,043
931
2,654
LT Debt
50
60
66
58
68
71
215
258
306
237
434
388
1,247
4,548
3,990
-526
7,932
Total Equity
5.35
12.05
12.5
- -
11.24
1.06
6.59
- -
0.89
- -
-26.57
- -
-63.16
15.18
- -
- -
- -
Return on Invested Capital (%)
5.53
10.95
12.01
- -
14.32
2.02
7.41
- -
-0.3
- -
-24.15
- -
-44.6
47.57
- -
- -
- -
Return on Capital (%)
6.21
12.97
15.19
-15.37
16.39
-0.23
7.65
-22.77
0.49
-50.3
-8.58
-10.48
-3.42
46.27
-47.15
- -
-8.56
Return on Common Equity (%)

Capital Structure

ARS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
519
414
414
LT Borrowings
931
1,573
2,654
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
43
43
43
Market Capitalization
10,136
6,601
6,729

Working Capital

ARS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,733
6,941
8,010
Cash, Cash Equivalents & STI
712
158
986
Accounts Receivable, Net
1,190
756
869
Inventories
2,608
3,606
3,734
Total Current Liabilities
6,605
4,936
4,472
Payables & Accruals
- -
- -
- -
ST Debt
519
414
414
Deferred Revenue
- -
- -
- -

Growth Rates

ARS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
65.34%
69.99%
-113.19%
Free Cash Flow
-704.2%
81.13%
-43.71%
Net Income, GAAP
-2,264.99%
-1,010.43%
146.6%
Sales/Revenue/Turnover
58.86%
72.25%
-41.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,056
2,197
2,299
1,820
10,886
2025
1,481
- -
1,747
2,130
6,404
2026
1,601
2,181
- -
- -
- -

Quarterly Earnings Per Share

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.63
-9.72
-3.28
-27.74
-43.78
2025
-19.16
- -
-32.55
-31.78
-107.95
2026
-11.36
65.47
- -
- -
- -

Quarterly Dividends Per Share

ARS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Instituto Rosenbusch S.A. is an Argentina-based animal health and veterinary pharmaceutical company engaged in the research, development, manufacturing, and commercialization of veterinary biologics, pharmaceuticals, and diagnostic solutions for livestock and companion animals. The company organizes its commercial and industrial operations primarily through two divisions: Biological Products and Pharmaceutical Products. Its biological portfolio encompasses viral and bacterial vaccines formulated for bovine, porcine, ovine, equine, and domestic pet health; diagnostic reagents and antigens, including Rose Bengal tests for bovine brucellosis screening; and biological vector control solutions, including biolarvicides. Its pharmaceutical portfolio includes broad-spectrum veterinary antibiotics and antimicrobials; internal and external antiparasitic treatments, comprising injectable endectocides, topical pour-on formulations, and oral anthelmintics; reproductive hormones and anti-inflammatory therapies; intramammary antimastitic medications; antifungal treatments; and metabolic nutrition solutions, including injectable vitamin, mineral, and amino acid complexes. The company also provides complementary livestock services, including veterinary laboratory diagnostics, epidemiology support, and electronic livestock identification and traceability systems. Founded in 1917 and formally incorporated in 1946, Instituto Rosenbusch S.A. is headquartered in Buenos Aires, Argentina. The company operates manufacturing laboratories and experimental agricultural research facilities in Buenos Aires province, alongside regional commercial subsidiaries and production assets in Uruguay, with commercial distribution extending across Paraguay, Brazil, and international export markets in the Americas, Europe, and the Asia-Pacific region. In recent developments, Instituto Rosenbusch S.A. underwent a major ownership and governance transition following the acquisition of an 80.16% controlling equity stake by investment group Agro 2000 S.A. in 2026, marking the exit of the founding family after several generations of control. This transaction prompted a mandatory public tender offer for the remaining 19.84% of outstanding Class B shares traded on Bolsas y Mercados Argentinos. Under its new ownership, the company has implemented a comprehensive strategic turnaround and balance-sheet restructuring following previous court-supervised insolvency proceedings, focusing on credit capitalization, technical asset revaluations, the modernization of its biological and pharmaceutical manufacturing infrastructure, and the expansion of its export capabilities across regional agricultural markets.